title: Circulating cell-derived microparticles in Crohn's disease.
abstract: Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn's disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn's disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn's disease. Circulating microparticle levels were elevated in patients with Crohn's disease (9.31+/-0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71+/-0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75+/-0.59 nmol/L PS Eq) and control subjects (4.06+/-0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33+/-1.20 to 6.45+/-0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn's disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn's disease.
authors.affiliation: Service d'Hepato-Gastroentérologie, et d'Assistance Nutritive, Hôpital de Hautepierre, 67098 Strasbourg Cedex, France. Patrick.Chamouard@chru-strasbourg.fr
authors.forename: Patrick
authors.initials: P
authors.lastname: Chamouard
authors.forename: Dominique
authors.initials: D
authors.lastname: Desprez
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Hugel
authors.forename: Corinne
authors.initials: C
authors.lastname: Kunzelmann
authors.forename: Carole
authors.initials: C
authors.lastname: Gidon-Jeangirard
authors.forename: Michel
authors.initials: M
authors.lastname: Lessard
authors.forename: René
authors.initials: R
authors.lastname: Baumann
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Freyssinet
authors.forename: Lélia
authors.initials: L
authors.lastname: Grunebaum
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D017209:Apoptosis; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D015331:Cohort Studies; D003092:Colitis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003424:Crohn Disease / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D011379:Prognosis; D012680:Sensitivity and Specificity; D013925:Thromboplastin
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; C053675:endothelial cell procoagulant activity; D013925:Thromboplastin; D000069285:Infliximab